Universität Duisburg-Essen Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial
2009
NCT01051167
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

Martin Schuler, Prof. Dr. med.

Active Ingredients

Drugs in Phase 2 Trials (3)

cetuximab (erbitux) (1 trial)

osimertinib (tagrisso) (1 trial)

ponatinib (iclusig) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Colorectal Neoplasms (Phase 2)

Gastrointestinal Stromal Tumors (Phase 2)

Lung Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 3